Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Moleculin Biotech ( (MBRX) ) has issued an update.
On December 17, 2025, Moleculin Biotech announced promising results from a physician-sponsored Phase 1 clinical trial of WP1066, conducted at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta. The trial, led by pediatric oncologist Dr. Tobey MacDonald, demonstrated WP1066’s safety profile and effectiveness in inducing anti-tumor immune responses for children with recurrent malignant brain tumors, such as high-grade glioma and diffuse intrinsic pontine glioma, conditions with limited existing treatments. These findings, published in the Journal of Clinical Investigation Insight, pave the way for a Phase 2 trial, potentially offering a novel treatment approach for these challenging pediatric cancers.
The most recent analyst rating on (MBRX) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
Spark’s Take on MBRX Stock
According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.
Moleculin Biotech’s stock score reflects a high-risk financial position with no revenue and growing losses typical of early-stage biotech firms. Positive developments in clinical trials and a solid financial runway provide potential upside, but significant risks remain due to financial instability, high trial costs, and future funding needs. Technical indicators suggest bearish momentum, and the valuation is unattractive due to the absence of earnings.
To see Spark’s full report on MBRX stock, click here.
More about Moleculin Biotech
Moleculin Biotech, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses. The company’s leading programs include Annamycin, aimed at treating relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases, and WP1066, an immune/transcription modulator designed to target cancers such as brain tumors and pancreatic cancer.
Average Trading Volume: 202,286
Technical Sentiment Signal: Sell
Current Market Cap: $9.69M
See more data about MBRX stock on TipRanks’ Stock Analysis page.